Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1122)	5/19/2000 7:52:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 52153

Q&A: What should I do about my biotech holdings? Eric: It depends on which stocks you hold. But the underlying fundamentals continue to be very favorable. By May 20 the annual American Society for Clinical Oncology conference will convene in New Orleans. And this event is likely to create a lot of excitement for the sector. Among companies that will be positively affected: ImClone Systems (NASDAQ: IMCL) Maxim Pharmaceuticals (NASDAQ: MAXM) Titan Pharmaceutical (NYSE: TTP) The important thing for biotech investors to remember is to only invest in companies that have concluded financings and have adequate cash reserves to fund research and development (R&D) activities over the next several years. Stay away from companies that couldn't price their offerings ahead of the recent market decline. In addition, it is very important for investors to be aware of when biotech companies are scheduled to release binary events (up or down/yes or no) because this news can have an either devastating or hugely positive effect on the share price. You don't want to be caught unknowingly holding stock in a biotech company you don't know much about just ahead of the release of clinical data or FDA hearings. Stay informed about the timing of significant milestones. individualinvestor.com Jim